The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N04 | Anti-parkinson drugs | |
3
|
N04B | Dopaminergic agents | |
4
|
N04BC | Dopamine agonists | |
5
|
N04BC05 | Pramipexole |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 2.5 mg |
| Active Ingredient |
|---|
|
Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. |
| Document | Type | Information Source | |
|---|---|---|---|
| MIRAPEX Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| MIRAPEXIN Tablet / Prolonged-release tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| SIFROL Prolonged-release tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| SIFROL Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.